Phase 2 MDX-1105 PD-L1 mAb trial

Investigators at UPMC are assessing whether discontinuing PD-L1 inhibitor therapy after one year maintains disease stability in patients with advanced solid tumors. The randomized study includes multiple tumor types such as ovarian, esophageal, breast, and NSCLC, among others, aiming to inform optimal treatment duration strategies.